GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLASCO Taiwan Co Ltd (ROCO:6662) » Definitions » Debt-to-Equity

BioLASCO Taiwan Co (ROCO:6662) Debt-to-Equity : 0.13 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioLASCO Taiwan Co Debt-to-Equity?

BioLASCO Taiwan Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$7.4 Mil. BioLASCO Taiwan Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$50.8 Mil. BioLASCO Taiwan Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$458.3 Mil. BioLASCO Taiwan Co's debt to equity for the quarter that ended in Mar. 2024 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioLASCO Taiwan Co's Debt-to-Equity or its related term are showing as below:

ROCO:6662' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.14   Max: 0.16
Current: 0.13

During the past 10 years, the highest Debt-to-Equity Ratio of BioLASCO Taiwan Co was 0.16. The lowest was 0.03. And the median was 0.14.

ROCO:6662's Debt-to-Equity is ranked better than
53.21% of 1058 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6662: 0.13

BioLASCO Taiwan Co Debt-to-Equity Historical Data

The historical data trend for BioLASCO Taiwan Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLASCO Taiwan Co Debt-to-Equity Chart

BioLASCO Taiwan Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.16 0.15 0.15 0.13

BioLASCO Taiwan Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.14 0.13 0.13

Competitive Comparison of BioLASCO Taiwan Co's Debt-to-Equity

For the Biotechnology subindustry, BioLASCO Taiwan Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLASCO Taiwan Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLASCO Taiwan Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioLASCO Taiwan Co's Debt-to-Equity falls into.



BioLASCO Taiwan Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioLASCO Taiwan Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

BioLASCO Taiwan Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLASCO Taiwan Co  (ROCO:6662) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


BioLASCO Taiwan Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioLASCO Taiwan Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLASCO Taiwan Co (ROCO:6662) Business Description

Traded in Other Exchanges
N/A
Address
3rd Floor, 316 Chong-yang Road, Taipei, TWN, 115
BioLASCO Taiwan Co Ltd is a biological experimental development company. The company has produced strains of laboratory rats and mice, including outbreed stocks, inbreed strains, and immunedeficient models. It offers reagent kit and equipment which include Allentown, Biomedical data system, PLAS LABS.

BioLASCO Taiwan Co (ROCO:6662) Headlines

No Headlines